Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | MDM4 | O15151 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11699464 | 0.86 | GAA (0.55) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL25482649 | 0.83 | RAB9A (0.60) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL3928165 | 0.82 | LNPEP (0.67) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL3928164 | 0.82 | LNPEP (0.67) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL31206887 | 0.82 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL2461492 | 0.82 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL1793176 | 0.82 | GAA (0.76) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL9159625 | 0.81 | GAA (0.61) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL9159630 | 0.81 | GAA (0.61) | RAB9AGAAALDH1A1LMNAGLA | |
| SCHEMBL11694765 | 0.81 | GAA (0.60) | RAB9AGAAALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2770977-B1 | NOVEL DOSAGE FORM | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-07-12 | — | — | EP | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| US-9271977-B2 | Sanglifehrin derivatives and methods for their production | NEUROVIVE PHARMACEUTICAL AB (SE) | 2016-03-01 | — | — | US | disclosed |
| EP-2691413-B1 | MACROCYCLIC COMPOUNDS AND METHODS FOR THEIR PRODUCTION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2014-12-24 | — | — | EP | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | Neurovive Pharmaceuticals AB (SE) | 2014-03-20 | — | — | US | disclosed |
| WO-2013061052-A1 | NOVEL DOSAGE FORM | BIOTICA TECHNOLOGY LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080837-A1 | Sanglifehrin Derivatives and Methods for Their Production | MAVS, HDGF, TTPA | RAB9A 911/4885GAA 2152/4885ALDH1A1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.